A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management

Postgraduate Medicine

Volumn 123, Issue 6, 2011, Pages 124-131

  McCarberg, Bill H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic pain; Education; Opioid treatment adherence

Indexed keywords

BUPRENORPHINE; CARISOPRODOL; CODEINE; DRUG METABOLITE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMORPHONE; QUETIAPINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAPENTADOL; TRAMADOL; TRAZODONE;

ARTICLE; CHRONIC PAIN; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; EDUCATION PROGRAM; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; NARCOTIC DEPENDENCE; PATIENT COMPLIANCE; POINT OF CARE TESTING; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; URINE DRUG TESTING;

ANALGESICS, OPIOID; CHRONIC PAIN; HUMANS; MEDICATION ADHERENCE; OPIOID-RELATED DISORDERS; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; URINALYSIS;

EID: 82155188988     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.11.2502     Document Type: Article

References (41)

1. McCarberg BH, Billington R. Consequences of neuropathic pain: quality-of-life issues and associated costs. Am J Manag Care. 2006;12(suppl 9):S263-S268.
2. Institute of Medicine of the National Academies. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Released June 29, 2011. http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx. Accessed September 22, 2011.
3. Zagari MJ, Mazonson PD, Longton WC. Pharmacoeconomics of chronic nonmalignant pain. Pharmacoeconomics. 1996;10(4):356-377.
4. Katz WA, Barkin RL. Dilemmas in chronic/persistent pain management. Am J Ther. 2008;15(3):256-264.
5. American Pain Society. Chronic pain in America: roadblocks to relief, a study conducted by Roper Starch Worldwide for American Academy of Pain Medicine, American Pain Society, and Janssen Pharmaceutica, 1999. http://www.ampainsoc.org/resources/roadblocks/summary2_road.htm. Accessed November 8, 2010.
6. Scanlon MN, Chugh U. Exploring physicians' comfort level with opioids for chronic noncancer pain. Pain Res Manag. 2004;9(4):195-201.
7. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
8. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27(3):260-267.
9. Evans M, Kriger S, Gunn J, Schwilke G. Effective monitoring of opiates in chronic pain patients. Practical Pain Management. 2009;9(6):32-33.
10. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008;11(suppl 2):S155-S180.
11. National Drug Intelligence Center, US Department of Justice. Methadone diversion, abuse, and misuse: deaths increasing at alarming rate. Product No. 2007-Q0317-001. November 2007. http://www.justice.gov/ndic/pubs25/25930/25930p.pdf. Accessed November 25, 2010.
12. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11(suppl 2):S5-S62.
13. Miller G. As Florida eyes mandatory urine drug testing, experts weigh in on ethics, role. Pain Med News. 2011;9(5). http://www.painmedicinenews.com/ViewArticle.aspx?d=Policy%2B%26amp%3B%2BManagement&d_id=83&i=May%2B2011&i_id=726&a_id=17081&ses =ogst. Accessed May 5, 2011.
14. Manchikanti L, Benyamin R, Datta S, Vallejo R, Smith H. Opioids in chronic noncancer pain. Expert Rev Neurother. 2010;10(5):775-789.
15. Melanson SE, Kredlow MI, Jarolim P. Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective. Clin Chem Lab Med. 2009;47(8): 971-976.
16. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307-315.
17. Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007;23(2):173-179.
18. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain. 1992;8(2):77-85.
19. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26(1):655-667.
20. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648-660.
21. Heit HA, Gourlay DL. DSM-V and the definitions: time to get it right. Pain Med. 2009;10(5):784-786.
22. Goldfarb B. Primary care physicians often miss signs of drug abuse in pain patients. Substance abuse is an insidious disease, often festering below the radar of clinicians. Pain Med News. 2005; 3(6). http://www.painmedicinenews.com/ViewArticle.aspx?d =Clinical+Pain+Medicine&d_id =82&i= December+2005&i_id = 120&a_id = 4287. Accessed May 5, 2011.
23. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002;18(suppl 4):S76-S82.
24. Ready LB, Sarkis E, Turner JA. Self-reported vs. actual use of medications in chronic pain patients. Pain. 1982;12(3):285-294.
25. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of selfreported drug use in chronic pain patients. Clin J Pain. 1999;15(3): 184-191.
26. Gilbert JW, Wheeler GR, Mick GE, et al. Urine drug testing in the treatment of chronic noncancer pain in a Kentucky private neuroscience practice: the potential effect of Medicare benefit changes in Kentucky. Pain Physician. 2010;13(2):187-194.
27. Evans M, Kriger S, Gunn J, Schwilke G. Compliance monitoring and effective risk mitigation strategy. Practical Pain Management. 2010;10(5):43-46.
28. Columbia University. Missed opportunity: national survey of primary care physicians and patients on substance abuse. 2000. http://www.eric.ed.gov/PDFS/ED452442.pdf. Accessed September 22, 2011.
29. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97(4):1097-1102.
30. Hammett-Stabler CA, Webster LR. A clinical guide to urine drug testing: augmenting pain management and enhancing patient care. Newark, NJ: UMDMJ-Center for Continuing and Outreach Education; 2008.
31. iCup [package insert]. Norfolk, VA: Instant Technologies; 2005.
32. Buckley NA. Abnormal laboratory results: drug screens. Australian Prescriber. 2001;24(4):90-91.
33. Centers for Medicare and Medicaid Services. Medicare fee schedules. http://www.cms.gov/ClinicalLabFeeSched/02_clinlab.asp#TopOfPage. Accessed January 4, 2011.
34. Pesce A, Rosenthal M, West R, et al. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician. 2010;13(3):273-281.
35. Shulman RW, Ozdemir V. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry. 1997;42(suppl 1):4S-9S.
36. Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev. 2009;12(5-6):334-361.
37. Pergolizzi J, Pappagallo M, Stauffer J, et al; Integrated Drug Compliance Study Group (IDCSG). The role of urine drug testing for patients on opioid therapy. Pain Pract. 2010;10(6):497-507.
38. Split-Specimen Cup [package insert]. Milwaukee, WI: Noble Medical; 2007.
39. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349-355.
40. Transmetron. UA tests: oxycodone-hydrocodone drug test. http://www.uatests.com/drug-test-by-drug/oxycodone.html. Accessed March 2, 2011.
41. Gourlay D, Heit HA. The art and science of urine drug testing. Clin J Pain. 2010;26(4):358.